New blood processing method could cut transfusion needs for sickle cell patients
NCT ID NCT06743113
First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study tests whether red blood cells processed to be low in oxygen (hypoxic) last longer in the body than standard cells for people with sickle cell anemia who need regular transfusions. About 48 participants aged 7 and older will receive both types of blood in a crossover design. The goal is to see if hypoxic cells slow the drop in healthy hemoglobin levels, potentially reducing how often transfusions are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hypoxic red blood cells processed with the Hemanext ONE system
- What this could lead to
- If it works, this could reduce how often patients with sickle cell anemia need transfusions, easing treatment burden.
- What could go wrong
- This is a small early-stage trial with only 48 participants, so results may not apply to everyone. The device is new, and long-term benefits or risks are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
John Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
-
New England Sickle Cell Institute, University of Connecticut
Farmington, Connecticut, 06030, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15260, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common drug shield children with sickle cell from stroke?
- Could a stronger dose of an old drug protect children with sickle cell from organ damage?
- Gene editing could cure sickle cell by boosting fetal hemoglobin
- Can a 90-Minute training improve care for kids with sickle cell?
- Sickle cell drug voxelotor tested for brain benefits in kids – study cut short
- Could pressurized oxygen ease sickle cell pain?